Literature DB >> 19906914

Wide-scale use of Notch signaling factor CSL/RBP-Jkappa in RTA-mediated activation of Kaposi's sarcoma-associated herpesvirus lytic genes.

Linda M Persson1, Angus C Wilson.   

Abstract

For Kaposi's sarcoma-associated herpesvirus (KSHV; also called human herpesvirus 8 [HHV8]), the switch from latency to active lytic replication requires RTA, the product of open reading frame 50 (ORF50). RTA activates transcription from nearly 40 early and delayed-early viral promoters, mainly through interactions with cellular DNA binding proteins, such as CSL/RBP-Jkappa, Oct-1, C/EBPalpha, and c-Jun. Reliance on cellular coregulators may allow KSHV to adjust its lytic program to suit different cellular contexts or interpret signals from the outside. CSL is a key component of the Notch signaling pathway and is targeted by several viruses. A search with known CSL binding sequences from cellular genes found at least 260 matches in the KSHV genome, many from regions containing known or suspected lytic promoters. Analysis of clustered sites located immediately upstream of ORF70 (thymidylate synthase), ORF19 (tegument protein), and ORF47 (glycoprotein L) uncovered RTA-responsive promoters that were validated using mRNAs isolated from KSHV-infected cells undergoing lytic reactivation. Notably, ORF19 behaves as a true late gene, indicating that RTA regulates all three phases of the lytic program. For each new promoter, the response to RTA was dependent on CSL, and 5 of the 10 candidate sites were shown to bind CSL in vitro. Analysis of individual sites highlighted the importance of a cytosine residue flanking the core CSL binding sequence. These findings broaden the role for CSL in coordinating the KSHV lytic gene expression program and help to define a signature motif for functional CSL sites within the viral genome.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19906914      PMCID: PMC2812342          DOI: 10.1128/JVI.01301-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  77 in total

1.  Kaposi's sarcoma-associated herpesvirus latent and lytic gene expression as revealed by DNA arrays.

Authors:  R G Jenner; M M Albà; C Boshoff; P Kellam
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

2.  Transcription pattern of human herpesvirus 8 open reading frame K3 in primary effusion lymphoma and Kaposi's sarcoma.

Authors:  P Rimessi; A Bonaccorsi; M Stürzl; M Fabris; E Brocca-Cofano; A Caputo; G Melucci-Vigo; M Falchi; A Cafaro; E Cassai; B Ensoli; P Monini
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  Octamer-binding sequence is a key element for the autoregulation of Kaposi's sarcoma-associated herpesvirus ORF50/Lyta gene expression.

Authors:  S Sakakibara; K Ueda; J Chen; T Okuno; K Yamanishi
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

4.  Transcription activation of polyadenylated nuclear rna by rta in human herpesvirus 8/Kaposi's sarcoma-associated herpesvirus.

Authors:  M J Song; H J Brown; T T Wu; R Sun
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

5.  Open reading frame 50 protein of Kaposi's sarcoma-associated herpesvirus directly activates the viral PAN and K12 genes by binding to related response elements.

Authors:  Pey-Jium Chang; Duane Shedd; Lyn Gradoville; Myung-Sam Cho; Lee-Wen Chen; Jimmy Chang; George Miller
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

6.  On the control of late gene expression in Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8).

Authors:  Jean Chang; Don Ganem
Journal:  J Gen Virol       Date:  2000-08       Impact factor: 3.891

7.  Kaposi's sarcoma-associated herpesvirus open reading frame 50/Rta protein activates the entire viral lytic cycle in the HH-B2 primary effusion lymphoma cell line.

Authors:  L Gradoville; J Gerlach; E Grogan; D Shedd; S Nikiforow; C Metroka; G Miller
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

8.  Characterization of interactions between RTA and the promoter of polyadenylated nuclear RNA in Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8.

Authors:  Moon Jung Song; Xudong Li; Helen J Brown; Ren Sun
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

Review 9.  Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma.

Authors:  Ulrich R Hengge; Thomas Ruzicka; Stephen K Tyring; Martin Stuschke; Michael Roggendorf; Robert A Schwartz; Siegfried Seeber
Journal:  Lancet Infect Dis       Date:  2002-06       Impact factor: 25.071

Review 10.  Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy.

Authors:  Ulrich R Hengge; Thomas Ruzicka; Stephen K Tyring; Martin Stuschke; Michael Roggendorf; Robert A Schwartz; Siegfried Seeber
Journal:  Lancet Infect Dis       Date:  2002-05       Impact factor: 25.071

View more
  38 in total

1.  Localization of sequences in a protein (ORF2) encoded by the latency-related gene of bovine herpesvirus 1 that inhibits apoptosis and interferes with Notch1-mediated trans-activation of the bICP0 promoter.

Authors:  Devis Sinani; Clinton Jones
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

2.  Carboxyl-terminal amino acids 1052 to 1082 of the latency-associated nuclear antigen (LANA) interact with RBP-Jκ and are responsible for LANA-mediated RTA repression.

Authors:  Yi Jin; Zhiheng He; Deguang Liang; Quanzhi Zhang; Hongxing Zhang; Qiang Deng; Erle S Robertson; Ke Lan
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

Review 3.  Molecular biology of Kaposi's sarcoma-associated herpesvirus and related oncogenesis.

Authors:  Qiliang Cai; Suhbash C Verma; Jie Lu; Erle S Robertson
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

4.  Cellular transcription factor Oct-1 interacts with the Epstein-Barr virus BRLF1 protein to promote disruption of viral latency.

Authors:  Amanda R Robinson; Swee Sen Kwek; Stacy R Hagemeier; Coral K Wille; Shannon C Kenney
Journal:  J Virol       Date:  2011-06-22       Impact factor: 5.103

5.  Kaposi's sarcoma-associated herpesvirus Rta tetramers make high-affinity interactions with repetitive DNA elements in the Mta promoter to stimulate DNA binding of RBP-Jk/CSL.

Authors:  Diana Palmeri; Kyla Driscoll Carroll; Olga Gonzalez-Lopez; David M Lukac
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

6.  Quantitative analysis of the bidirectional viral G-protein-coupled receptor and lytic latency-associated nuclear antigen promoter of Kaposi's sarcoma-associated herpesvirus.

Authors:  Isaac B Hilton; Dirk P Dittmer
Journal:  J Virol       Date:  2012-06-27       Impact factor: 5.103

7.  IL-10 promoter transactivation by the viral K-RTA protein involves the host-cell transcription factors, specificity proteins 1 and 3.

Authors:  Masanori Miyazawa; Kohji Noguchi; Mana Kujirai; Kazuhiro Katayama; Satoshi Yamagoe; Yoshikazu Sugimoto
Journal:  J Biol Chem       Date:  2017-11-28       Impact factor: 5.157

8.  Identification of Novel Kaposi's Sarcoma-Associated Herpesvirus Orf50 Transcripts: Discovery of New RTA Isoforms with Variable Transactivation Potential.

Authors:  Brian S Wakeman; Yoshihiro Izumiya; Samuel H Speck
Journal:  J Virol       Date:  2016-12-16       Impact factor: 5.103

9.  Helminth infection reactivates latent γ-herpesvirus via cytokine competition at a viral promoter.

Authors:  T A Reese; B S Wakeman; H S Choi; M M Hufford; S C Huang; X Zhang; M D Buck; A Jezewski; A Kambal; C Y Liu; G Goel; P J Murray; R J Xavier; M H Kaplan; R Renne; S H Speck; M N Artyomov; E J Pearce; H W Virgin
Journal:  Science       Date:  2014-06-26       Impact factor: 47.728

10.  Cohesins repress Kaposi's sarcoma-associated herpesvirus immediate early gene transcription during latency.

Authors:  Horng-Shen Chen; Priyankara Wikramasinghe; Louise Showe; Paul M Lieberman
Journal:  J Virol       Date:  2012-06-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.